Skip to main content

Table 2 Clinical findings in the treatment and control group post-treatment

From: Safety of concurrent treatment of dogs with fluralaner (Bravecto™) and milbemycin oxime - praziquantel

  Number of dogs affected
  Treatment group* Control group**
Single small and mild skin lesions (scar/papilloma/sore spots/alopecia/erythema/laceration/graze/scab/scaling) 4 7
Small amount of serous eye discharge 2 1
Sinus arrhythmia 1: day 28 (1: day -7)
Loose feces with normal feces 1: day 7 0
Others 1 excess ear wax, 2 dental tartar 1 penile discharge, 1 dental tartar, 1 transient limping
  1. *None of these observations was considered to be treatment related, because a similar incidence occurred in the control group, they were already observed pre-treatment and/or the long interval between treatment and occurrence. All observations were common findings in a dog colony.
  2. **None of these observations was considered to be treatment related, because they were already observed pre-treatment and/or are common findings in a dog colony.
\